Developing novel bioconjugates for the detection and treatment of bladder disease.

Bladder cancers are the 5th most common cancer.
- high rates of recurrence
- high cost of surveillance and treatment
- amenable to targeted treatment by intravesicular drug delivery, avoiding systemic exposure.

Currently there are no targeted reagents available for bladder cancer treatment or detection.

We have discovered a novel pathway for the targeted delivery of agents to the cell interior.
This pathway is being exploited first to create new targeting bioconjugates for the treatment, detection, and surveillance of bladder cancers.*

*patent pending

John L. Muschler, PhD. Biomedical Engineering, OHSU. Email: muschler@ohsu.edu